The DOI matches its Crossref record; 294 of the 296 references it cites were found in a registry or an index.
Biomarkers for the Early Detection and Progression of Alzheimer's Disease
Open accessAbstract
The recent failures of potential disease-modifying drugs for Alzheimer's disease (AD) may reflect the fact that the enrolled participants in clinical trials are already too advanced to derive a clinical benefit. Thus, well-validated biomarkers for the early detection and accurate diagnosis of the preclinical stages of AD will be crucial for therapeutic advancement. The combinatorial use of biomarkers derived from biological fluids, such as cerebrospinal fluid (CSF), with advanced molecular imaging and neuropsychological testing may eventually achieve the diagnostic sensitivity and specificity necessary to identify people in the earliest stages of the disease when drug modification is most likely possible. In this regard, positive amyloid or tau tracer retention on positron emission tomography imaging, low CSF concentrations of the amyloid-β 1-42 peptide, high CSF concentrations in total tau and phospho-tau, mesial temporal lobe atrophy on magnetic resonance imaging, and temporoparietal/precuneus hypometabolism or hypoperfusion on 18F-fluorodeoxyglucose positron emission tomography have all emerged as biomarkers for the progression to AD. However, the ultimate AD biomarker panel will likely involve the inclusion of novel CSF and blood biomarkers more precisely associated with confirmed pathophysiologic mechanisms to improve its reliability for detecting preclinical AD. This review highlights advancements in biological fluid and imaging biomarkers that are moving the field towards achieving the goal of a preclinical detection of AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies revealed that Aβ began to accumulate up to 15–20 years prior to clinical symptoms of Alzheimer’s disease42,43.”
From Integrated algorithm combining plasma biomarkers and cognitive assessments accurately predicts brain β-amyloid pathology (2023) · cites this paper as [43]
Citations
Cites
Items 201–294 of 294
Lysosomal Network Proteins as Potential Novel CSF Biomarkers for Alzheimer’s Disease
Armstrong, A., Mattsson, N., Appelqvist, H., Janefjord, C., Sandin, L., Agholme, L., Olsson, B., Svensson, S., Blennow, K., Zetterberg, H., et al. (2013) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8269-3 · Cited by 113
Sojkova, J., Driscoll, I. F., Iacono, D., Zhou, Y., Codispoti, K.-E., Kraut, M. A., Ferrucci, L., Pletniková, O., Mathis, C. A., Klunk, W. E., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.357 · Cited by 113
Алексеевна, Г. М., Davidova, T. B., Mališauskas, M., Sewell, R. D. E., Voskresenskaya, N. I., Wilhelm, K., Elistratova, E. I., Sherstnev, V. V., & Morozova‐Roche, L. A. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.03.023 · Cited by 112
Sole, A. D., Clerici, F., Chiti, A., Lecchi, M., Mariani, C. B., Maggiore, L., Mosconi, L., & Lucignani, G. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0773-6 · Cited by 112
Harada, R., Okamura, N., Furumoto, S., Tago, T., Maruyama, M., Higuchi, M., Yoshikawa, T., Arai, H., Iwata, R., Kudo, Y., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2261-2 · Cited by 111
PET Quantification of Tau Pathology in Human Brain with 11C-PBB3
Kimura, Y., Ichise, M., Ito, H., Shimada, H., Ikoma, Y., Seki, C., Takano, H., Kitamura, S., Shinotoh, H., Kawamura, K., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.160127 · Cited by 111
Lautner, R., Palmqvist, S., Mattsson, N., Andréasson, U., Wallin, A., Pålsson, E., Jakobsson, J., Herukka, S., Owenius, R., Olsson, B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1060 · Cited by 110
CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease
Tarawneh, R. M., Lee, J., Ladenson, J. H., Morris, J. C., & Holtzman, D. M. (2012) · Neurology · doi:10.1212/wnl.0b013e318248e568 · Cited by 107
Plasma 24-metabolite Panel Predicts Preclinical Transition to Clinical Stages of Alzheimer’s Disease
Fiandaca, M. S., Zhong, X., Cheema, A. K., Orquiza, M. H., Chidambaram, S., Tan, M. T., Gresenz, C. R., Fitzgerald, K. T., Nalls, M. A., Singleton, A., et al. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00237 · Cited by 107
Liu, C., Wang, J., Li, L., & Wang, P. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1780 · Cited by 107
Toledo, J. B., Korff, A., Shaw, L. M. J., Trojanowski, J. Q., & Zhang, J. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1148-z · Cited by 106
Three-dimensional Patterns of Hippocampal Atrophy in Mild Cognitive Impairment
Becker, J. T. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.97 · Cited by 106
Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly
Chhatwal, J. P., Schultz, A. P., Marshall, G. A., Boot, B., Gomez-Isla, T., Dumurgier, J., LaPoint, M., Scherzer, C., Roe, A. D., Hyman, B. T., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003050 · Cited by 106
Grimmer, T., Tholen, S., Yousefi, B. H., Alexopoulos, P., Förschler, A., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Perneczky, R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.013 · Cited by 105
Characteristics of Tau and Its Ligands in PET Imaging
Harada, R., Okamura, N., Furumoto, S., Tago, T., Yanai, K., Arai, H., & Kudo, Y. (2016) · Biomolecules · doi:10.3390/biom6010007 · Cited by 104
Leoni, V. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.088 · Cited by 102
Barthel, H., Luthardt, J., Becker, G., Patt, M., Hammerstein, E., Hartwig, K., Eggers, B., Sattler, B., Schildan, A., Hesse, S., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1821-1 · Cited by 101
Lockhart, S. N., Baker, S. L., Okamura, N., Furukawa, K., Ishiki, A., Furumoto, S., Tashiro, M., Yanai, K., Arai, H., Kudo, Y., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158460 · Cited by 100
In vivo assessment of amyloid‐β deposition in nondemented very elderly subjects
Mathis, C. A., Kuller, L. H., Klunk, W. E., Snitz, B. E., Price, J. C., Weissfeld, L. A., Rosario, B. L., Lopresti, B. J., Saxton, J. A., Aizenstein, H. J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23797 · Cited by 98
In vivo mapping of amyloid toxicity in Alzheimer disease
Frisoni, G. B., Lorenzi, M., Caroli, A., Kemppainen, N. M., Någren, K., & Rinne, J. O. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a2e896 · Cited by 97
Hippocampal atrophy and EEG markers in subjects with mild cognitive impairment
Moretti, D. V., Miniussi, C., Frisoni, G. B., Geroldi, C., Zanetti, O. O., Binetti, G. G., & Rossini, P. M. (2007) · Clinical Neurophysiology · doi:10.1016/j.clinph.2007.09.059 · Cited by 97
Di Domenico, F., Pupo, G., Giraldo, E., Badìa, M.-C., Monllor, P., Lloret, A., Eugenia Schininà, M., Giorgi, A., Cini, C., Tramutola, A., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.12.004 · Cited by 97
Soluble multimeric Alzheimer β(1–40) pre-amyloid complexes in dilute solution
LeVine, H. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00052-g · Cited by 95
Bangen, K. J., Restom, K., Liu, T. T., Wierenga, C. E., Jak, A. J., Salmon, D. P., & Bondi, M. W. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120292 · Cited by 92
Amyloid-β Immunotherapy for Alzheimers Disease
Fu, H., Liu, B., Frost, J. L., & Lemere, C. A. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012017 · Cited by 92
Mevel, K., Desgranges, B., Baron, J., Landeau, B., Sayette, V. D. L., Viader, F., Eustache, F., & Chételat, G. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.04.048 · Cited by 90
Pomara, N., Willoughby, L. M., Sidtis, J. J., & Mehta, P. D. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.10.914 · Cited by 88
Ikonomović, M. D., Abrahamson, E. E., Price, J. C., Hamilton, R. L., Mathis, C. A., Paljug, W. R., Debnath, M. L., Cohen, A. D., Mizukami, K., DeKosky, S. T., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0943-2 · Cited by 87
β-Amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer’s disease
Andreasen, N., & Blennow, K. (2002) · Peptides · doi:10.1016/s0196-9781(02)00056-6 · Cited by 86
Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease
Ikonomović, M. D., Klunk, W. E., Abrahamson, E. E., Wuu, J., Mathis, C. A., Scheff, S. W., Mufson, E. J., & DeKosky, S. T. (2011) · Neurology · doi:10.1212/wnl.0b013e3182231419 · Cited by 82
Self-citationConcentrations of amyloid β protein in cerebrospinal fluid of patients with alzheimer's disease
van Gool, W. A., Walstra, G. J. M., Bolhuis, P. A., Kuiper, M. A., & Wolters, E. C. (1995) · Annals of Neurology · doi:10.1002/ana.410370221 · Cited by 82
Mosconi, L., Santi, S. D., Li, Y., Li, J., Zhan, J., Tsui, W. H., Boppana, M., Pupi, A., & de Leon, M. J. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1956-z · Cited by 81
DiFrancesco, J. C., Longoni, M., & Piazza, F. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00207 · Cited by 80
Kapaki, E., Paraskevas, G. P., Zalonis, I., & Zournas, C. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00562.x · Cited by 80
Nonlinear time course of brain volume loss in cognitively normal and impaired elders
Schuff, N. W., Tosun, D., Insel, P. S., Chiang, G. C.-Y., Truran, D., Aisen, P. S. S., Jack, C. R., & Weiner, M. W. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.07.012 · Cited by 80
Lister‐James, J., Pontecorvo, M. J., Clark, C. M., Joshi, A. D., Mintun, M. A., Zhang, W., Lim, N. C., Zhuang, Z., Golding, G., Choi, S., et al. (2011) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2011.03.001 · Cited by 79
Ishiki, A., Okamura, N., Furukawa, K., Furumoto, S., Harada, R., Tomita, N., Hiraoka, K., Watanuki, S., Ishikawa, Y., Tago, T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140311 · Cited by 77
Ante mortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies
Kantarci, K., Yang, C., Schneider, J. A., Senjem, M. L., Reyes, D. A., Lowe, V. J., Barnes, L. L., Aggarwal, N. T., Bennett, D. A., Smith, G. E., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.08.007 · Cited by 72
Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions
Villemagne, V. L., & Okamura, N. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.09.002 · Cited by 70
Mecocci, P., Parnetti, L., Romano, G., Scarelli, A., Chionne, F., Cecchetti, R., Polidori, M. C., Palumbo, B., Cherubini, A., & Senin, U. (1995) · Journal of Neuroimmunology · doi:10.1016/0165-5728(94)00180-v · Cited by 69
Positron emission tomography radioligands for in vivo imaging of Aβ plaques
Mason, N. S., Mathis, C. A., & Klunk, W. E. (2013) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.2989 · Cited by 68
Amyloid imaging: Past, present and future perspectives
Villemagne, V. L. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.005 · Cited by 68
Tago, T., Furumoto, S., Okamura, N., Harada, R., Adachi, H., Ishikawa, Y., Yanai, K., Iwata, R., & Kudo, Y. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.166652 · Cited by 66
Visualization of regional tau deposits using 3H-THK5117 in Alzheimer brain tissue
Lemoine, L., Saint‐Aubert, L., Marutle, A., Antoni, G., Eriksson, J., Ghetti, B. F., Okamura, N., Nennesmo, I., Gillberg, P.-G., & Nordberg, A. K. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0220-4 · Cited by 65
Phosphorylated tau predicts rate of cognitive decline in MCI subjects: A comparative CSF study
Büerger, K., Ewers, M., Andreasen, N. C., Zinkowski, R. P., Ishiguro, K., Vanmechelen, E., Teipel, S. J., Graz, C., Blennow, K., & Hampel, H. J. (2005) · Neurology · doi:10.1212/01.wnl.0000183284.92920.f2 · Cited by 65
Comparison of New Tau PET-Tracer Candidates With [ 18 F]T808 and [ 18 F]T807
Declercq, L., Celen, S., Lecina, J., Ahamed, M., Tousseyn, T., Moechars, D., Alcázar, J., Ariza, M., Fierens, K., Bottelbergs, A., et al. (2016) · Molecular Imaging · doi:10.1177/1536012115624920 · Cited by 63
Büerger, K., Frisoni, G. B., Uspenskaya, O., Ewers, M., Zetterberg, H., Geroldi, C., Binetti, G. G., Johannsen, P., Rossini, P. M., Wahlund, L., et al. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.06.003 · Cited by 63
Colasanti, T., Barbati, C., Rosano, G. M. C., Malorni, W., & Ortona, E. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.07.008 · Cited by 61
Synapse Stability in the Precuneus Early in the Progression of Alzheimer's Disease
Scheff, S. W., PRICE, D. A., Schmitt, F. A., Roberts, K. N., Ikonomović, M. D., & Mufson, E. J. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122353 · Cited by 60
Self-citationHeurling, K., Leuzy, A., Zimmer, E. R., Lubberink, M., & Nordberg, A. K. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3208-1 · Cited by 59
Antibody drugs for Alzheimer’s show glimmers of promise
Reardon, S. (2015) · Nature · doi:10.1038/nature.2015.18031 · Cited by 55
Farlow, M. R. (1992) · The Lancet · doi:10.1016/0140-6736(92)91771-y · Cited by 55
Toward a multifactorial model of Alzheimer disease
Storandt, M., Head, D. M., Fagan, A. M., Holtzman, D. M., & Morris, J. C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.11.029 · Cited by 54
Kiddle, S. J., Steves, C. J., Mehta, M. A., Simmons, A., Xu, X., Newhouse, S., Sattlecker, M., Ashton, N. J., Bazenet, C. E., Killick, R., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.78 · Cited by 51
Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease
Roe, C. M., Fagan, A. M., Williams, M., Ghoshal, N., Aeschleman, M., Grant, E., Marcus, D. S., Mintun, M. A., Holtzman, D. M., & Morris, J. C. (2011) · Neurology · doi:10.1212/wnl.0b013e31820af900 · Cited by 49
Skillbäck, T. B., Zetterberg, H., Blennow, K., & Mattsson, N. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt212 · Cited by 49
Non-stiff anti-amphiphysin syndrome: Clinical manifestations and outcome after immunotherapy
Moon, J., Lee, S., Shin, J.-W., Byun, J., Lim, J., Shin, Y., Kim, T., Lee, K., Park, K., Jung, K., et al. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.07.011 · Cited by 49
Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease
Leko, M. B., Štrac, D. Š., Mück‐Šeler, D., Pivac, N., Stanić, G., Hof, P. R., & Šimić, G. (2014) · Croatian Medical Journal · doi:10.3325/cmj.2014.55.347 · Cited by 48
Karczewski, P., Hempel, P., Kunze, R., & Bimmler, M. (2012) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2012.02684.x · Cited by 48
Cerebral Metabolic Correlates of the Clinical Dementia Rating Scale in Mild Cognitive Impairment
Perneczky, R., Hartmann, J., Grimmer, T., Drzezga, A. E., & Kurz, A. (2007) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988706297093 · Cited by 47
Role of cholesterol metabolism in the pathogenesis of Alzheimerʼs disease
Allinquant, B., Clamagirand, C., & Potier, M.-C. (2014) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0000000000000069 · Cited by 47
Cerebrospinal fluid antibodies to oxidized LDL are increased in Alzheimer's disease
Kankaanpää, J., Turunen, S. P., Moilanen, V., Hörkkö, S., & Remes, A. M. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.12.001 · Cited by 45
Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer's Disease
Counts, S., He, B., Prout, J. G., Michalski, B., Farotti, L., Fahnestock, M. L., & Mufson, E. J. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160129095649 · Cited by 45
Self-citationUtility of Autoantibodies as Biomarkers for Diagnosis and Staging of Neurodegenerative Diseases
DeMarshall, C. A., Sarkar, A., Nagele, E. P., Goldwaser, E. L., Godsey, G. A., Acharya, N. K., & Nagele, R. G. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.05.005 · Cited by 44
Mukaetova-Ladinska, E., Milne, J., Andras, A., Abdel‐All, Z., Cerejeira, J., Greally, E., Robson, J., Jaros, E., Perry, R., McKeith, I. G., et al. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000141039 · Cited by 44
A Candidate Plasma Protein Classifier to Identify Alzheimer's Disease
Zhao, X., Lejnine, S., Spond, J., Zhang, C., Ramaraj, T. C., Holder, D., Dai, H. A., WEINER, R. S., & Laterza, O. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141149 · Cited by 43
Identification of Aldolase as a Target Antigen in Alzheimer’s Disease
Mor, F., Izak, M., & Cohen, I. R. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.5.3439 · Cited by 43
Vacirca, D., Delunardo, F., Matarrese, P., Colasanti, T., Margutti, P., Siracusano, A., Pontecorvo, S., Capozzi, A., Sorice, M., Francia, A., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.013 · Cited by 41
Technical Considerations in Brain Amyloid PET Imaging with 18F-Florbetapir
Trembath, L., Newell, M., & Devous, M. D. (2015) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.115.156679 · Cited by 39
Elevated Levels of τ and Ubiquitin in Brain and Cerebrospinal Fluid in Alzheimer’s Disease
Iqbal, K., & Grundke, I. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297005024 · Cited by 39
Tiernan, C. T., Ginsberg, S. D., Guillozet-Bongaarts, A. L., Ward, S., He, B., Kanaan, N. M., Mufson, E. J., Binder, L. I., & Counts, S. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.031 · Cited by 38
Self-citationPettigrew, C., Soldan, A., Moghekar, A., Wang, M.-C., Gross, A. L., O’Brien, R., & Albert, M. (2015) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2015.09.024 · Cited by 38
Busse, S., Brix, B., Kunschmann, R., Bogerts, B., Stoecker, W., & Busse, M. (2014) · Neuroscience Research · doi:10.1016/j.neures.2014.06.002 · Cited by 37
Pittsburgh compound B and the postmortem diagnosis of alzheimer disease
Niedowicz, D. M., Beckett, T. L., Matveev, S., Weidner, A. M., Baig, I., Kryscio, R. J., Mendiondo, M. S., LeVine, H., Keller, J. N., & Murphy, M. P. (2012) · Annals of Neurology · doi:10.1002/ana.23633 · Cited by 37
Florbetaben for PET Imaging of Beta-Amyloid Plaques in the Brain
Richards, D., & Sabbagh, M. N. (2014) · Neurology and Therapy · doi:10.1007/s40120-014-0022-9 · Cited by 32
Multimodal MRI ‐based imputation of the A β + in early mild cognitive impairment
Tosun, D., Joshi, S. C., Weiner, M. W., & Initiative, A. D. N. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.40 · Cited by 32
An aberrant protein complex in CSF as a biomarker of Alzheimer disease
Lovell, M. A., Lynn, B. C., Xiong, S., Quinn, J. F., Kaye, J. A., & Markesbery, W. R. (2008) · Neurology · doi:10.1212/01.wnl.0000312383.39973.88 · Cited by 32
Autoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer’s Disease
Giil, L. M., Kristoffersen, E. K., Vedeler, C. A., Aarsland, D., Nordrehaug, J. E., Winblad, B. G., Cedazo-Mı́nguez, Á., Lund, A., & Reksten, T. R. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150053 · Cited by 28
Synthesis and quality control of [18F]T807 for tau PET imaging
Holt, D. P., Ravert, H. T., & Dannals, R. F. (2016) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3425 · Cited by 28
Koval, L., Lykhmus, O., Kalashnyk, O., Bachinskaya, N. Y., Kravtsova, G., Soldatkina, M. A., Zouridakis, M., Stergiou, C., Tzartos, S. J., Tsetlin, V. I., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101845 · Cited by 24
Wang, H., Golob, E. J., Bert, A., Nie, K., Chu, Y., Dick, M. B., Mandelkern, M. A., & Su, M. (2008) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988708328212 · Cited by 24
Hempel, P., Heinig, B., Jerosch, C., Decius, I., Karczewski, P., Kassner, U., Kunze, R., Steinhagen‐Thiessen, E., & Bimmler, M. (2016) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12415 · Cited by 23
Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer’s disease
McIntyre, J. A., Ramsey, C. J., Gitter, B. D., Saykin, A. J., Wagenknecht, D. R., Hyslop, P. A., & Initiative, F. T. A. D. N. (2015) · Autoimmunity · doi:10.3109/08916934.2015.1008464 · Cited by 22
Induction of autoantibodies to glutamate in patients with Alzheimer’s disease
Davydova, T. V., Voskresenskaya, N. I., Fomina, V. G., Vetrilé, L. A., & Doronina, O. A. (2007) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-007-0044-8 · Cited by 21
Postmortem Pittsburgh Compound B (PiB) Binding Increases with Alzheimer's Disease Progression
Beckett, T. L., Webb, R. L., Niedowicz, D. M., Holler, C. J., Matveev, S., Baig, I., LeVine, H., Keller, J. N., & Murphy, M. P. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120655 · Cited by 20
Low Levels of Antibodies Against Phosphorylcholine in Alzheimer's Disease
Eriksson, U. K., Sjöberg, B. G., Bennet, A. M., Fairé, U. D., Pedersen, N. L., & Frostegård, J. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091705 · Cited by 15
Vacirca, D., Barbati, C., Scazzocchio, B., Masella, R., Rosano, G. M. C., Malorni, W., & Ortona, E. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110350 · Cited by 14
Putative CSF protein biomarker candidates for amnestic mild cognitive impairment
Counts, S., & Mufson, E. J. (2010) · Translational Neuroscience · doi:10.2478/v10134-010-0004-0 · Cited by 13
Self-citationAutoantibodies to GM1 and GQ1bα are not Biological Markers of Alzheimer's Disease
Miura, Y., Miyaji, K., Chai, Y. L., Chen, C., Lai, M. K. P., & Yuki, N. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140474 · Cited by 13
McIntyre, J. A., Wagenknecht, D. R., & Ramsey, C. J. (2009) · Autoimmunity · doi:10.3109/08916930903074833 · Cited by 13
Vitamin D and Neurocognitive Disorder Due to Alzheimer's Disease: A Review of the Literature
Wood, J. M., & Gupta, S. (2015) · Annals of Clinical Psychiatry · doi:10.1177/104012371502700307 · Cited by 11
Delunardo, F., Margutti, P., Pontecorvo, S., Colasanti, T., Conti, F., Riganò, R., Profumo, E., Siracusano, A., Capozzi, A., Prencipe, M., et al. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.09.027 · Cited by 11
Anti-Chol-1 Antigen, GQ1bα, Antibodies Are Associated with Alzheimer’s Disease
Ariga, T., Kubota, M., Nakane, M., Oguro, K., Yu, R. K., & Ando, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063326 · Cited by 11
Price (1999) · doi:10.1002/1531-8249(199903)45:3
Cited by
Sorted by citations
van Oostveen, W. M., & de Lange, E. C. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042110 · Cited by 297
Barone, E., Domenico, F. D., Marzia Perluigi, A., & Butterfield, D. A. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.09.006 · Cited by 182
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
The emerging role of exosomes in Alzheimer’s disease
Zhang, T., Ma, S., Lv, J., Wang, X., Afewerky, H. K., Li, H. R., & Lu, Y. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101321 · Cited by 141
Dhiman, K., Blennow, K., Zetterberg, H., Martins, R. N., & Gupta, V. B. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03040-5 · Cited by 117
Metadata
- Authors
- Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J.
- Affiliations
- Trinity Health Grand Rapids (US)
- Michigan State University (US)
- Barrow Neurological Institute (US)
- Corresponding author
- Mufson, Elliott J.
- Venue
- Neurotherapeutics
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 14
- Issue
- 1
- Pages
- 35-53
- ISSN
- 1878-7479 (ISSN-L)
- PMC
- PMC5233625
- OpenAlex
- W2529983878
- Cited by
- 224
- References
- 296
- Citations by year
- 2026: 23 · 2025: 25 · 2024: 35 · 2023: 27 · 2022: 24 · 2021: 33 · 2020: 22 · 2019: 18 · 2018: 11 · 2017: 3
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Neurotherapeutics (publishedVersion, other-oa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG043375, AG026032)
- National Intitute on Aging (AG042146)
- BNI Barrow and Beyond
- Saint Mary’s Foundation
- Miles for Memories of Battle Creek
- National Insitute of Aging (PO1AG025204)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, biomarkers, early detection, preclinical Alzheimer's disease, disease progression, cerebrospinal fluid biomarkers, amyloid-beta 42, total tau, phosphorylated tau, amyloid PET, tau PET, FDG-PET, blood biomarkers
- MeSH terms
- Alzheimer Disease, Autoantibodies, Humans, Sensitivity and Specificity, Biomarkers, Amyloid beta-Peptides, Disease Progression, Inflammation Mediators, Early Diagnosis, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
